^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DO-2

    i
    Other names: DO-2, deuterated OMO-2
    Associations

    News

    Trials
    Company:
    DeuterOncology, J&J, Octimet
    Drug class:
    c-MET inhibitor, RAS inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours (clinicaltrials.gov)
    P1, N=25, Recruiting, DeuterOncology | Trial completion date: Apr 2025 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    MET mutation
    |
    DO-2
    8ms
    Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
    P1, N=25, Recruiting, DeuterOncology | N=15 --> 25 | Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Oct 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MET mutation
    |
    DO-2
    over1year
    Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
    P1, N=15, Recruiting, DeuterOncology | Active, not recruiting --> Recruiting | Trial completion date: Jun 2024 --> Nov 2024
    Enrollment open • Trial completion date • Metastases
    |
    MET mutation
    |
    DO-2